SCHEMBL5481564

SCHEMBL5481564

CC[C@H](C)NC(=O)N1CC(OC(c2ccc(Cl)cc2)c2ccccc2Cl)C1.O=C(NCc1ccsc1Br)N1CC(OC(c2ccc(Cl)cc2)c2ccccc2Cl)C1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FAAH O00519 15/20 0.43
CNR1 P21554 3/20 0.40
CNR2 P34972 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077288 0.92 FAAH (0.43) FAAHCNR1CNR2
SCHEMBL5798997 0.92 FAAH (0.39) FAAHCNR1CNR2
SCHEMBL4084842 0.87 FAAH (0.53) FAAHCNR1CNR2
SCHEMBL4075866 0.87 FAAH (0.53) FAAHCNR1CNR2
SCHEMBL4077682 0.80 FAAH (0.42) FAAHCNR1CNR2
SCHEMBL4077693 0.78 MEN1 (0.54) FAAHCNR1CNR2
SCHEMBL29574541 0.78 MEN1 (0.54) FAAHCNR1CNR2
SCHEMBL4082474 0.77 FAAH (0.49) FAAHCNR1CNR2
SCHEMBL4089341 0.76 CNR1 (0.52) FAAHCNR1CNR2
SCHEMBL29574730 0.76 CNR1 (0.52) FAAHCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054891-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders VERNALIS RESEARCH LIMAITED (GB) 2007-03-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054891-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders CNR1, CNR2, GPR119 FAAH 8/4885CNR1 1/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.